SAT-135 Clinical Outcomes for Patients with PCOS and COVID 19: An Analysis of the National Inpatient Sample

Abstract Disclosure: D.C. Thor: None. T. Elias: None. M. Singh: None. S. Prasad: None. Clinical Outcomes for Patients with PCOS and COVID-19: An Analysis of the National Inpatient SampleIntroduction: As clinicians continue to improve their recognition and management of polycystic ovarian syndrome (PCOS), it remains imperative to understand the health outcomes for these patients over time. Limited data is available on the comorbid correlations for the PCOS population.Objectives: We sought to examine the National Inpatient Sample (NIS) database to describe in-hospital outcomes among patients with PCOS and an active COVID-19 infection.Methods: Data were extracted from the NIS database from 2019 and 2020. The NIS was searched for hospitalizations of all patients greater than 18 years old who had PCOS. We then analyzed the outcomes of patients with COVID-19. Multivariate logistic regression analysis was used to adjust for confounders. The primary outcome was inpatient mortality and secondary outcomes were annotated accordingly. SPSS software was used for statistical analysis, and all results were powered to p<0.001.Results: This study included 32,385 patients with PCOS, of which 586 (1.81%) were identified as having an active COVID-19 infection. Multivariate regression demonstrated that COVID-19 patients with PCOS had higher inpatient mortality (OR 1.160, CI 1.066-1.262, p<0.001). On secondary analysis, PCOS patients with COVID-19 were more likely to have systemic lupus erythematosus (OR 1.025, CI 1.005-1.046), anemia (OR 1.016, CI 1.013-1.019), thrombocytopenia (OR 1.037, CI 1.024-1.050), hypertension (OR 1.022, CI 1.013-1.030), chronic kidney disease (OR 1.020, CI 1.010-1.030), acute renal failure (OR 1.038, CI 1.027-1.049), chronic obstructive pulmonary disease (OR 1.020, CI 1.009-1.032), pulmonary hypertension (OR 1.021, CI 1.003-1.040), severe liver disease (OR 1.013, CI 1.003-1.024), all-cause arrhythmias (OR 1.019, CI 1.009-1.028), all-cause shock (OR 1.060, CI 1.015-1.107), all-cause heart block (OR 1.026, CI 1.001-1.052), all-cause sepsis (OR 1.049, CI 1.041-1.058), all-cause coagulopathy (OR 1.031, CI 1.020-1.042), all-cause heart failure (OR 1.022, CI 1.012-1.032), all-cause stroke (OR 1.023, CI 1.012-1.034), and all-cause myocardial infarction (OR 1.023, CI 1.008-1.039).Conclusion: In this nationally-representative, population-based retrospective cohort study, hospitalized patients with PCOS and COVID-19 were associated with higher mortality and worse outcomes. Further analysis and/or discussion is necessary to improve the care of this potentially underserved population. Presentation: Saturday, July 12, 2025

Authors

Institutions

Publication Details

Journal
Journal of the Endocrine Society
Published
2025-10-01
DOI
https://doi.org/10.1210/jendso/bvaf149.1985
Primary Topic
Diagnosis and Treatment of Venous Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

SAT-135 Clinical Outcomes for Patients with PCOS and COVID 19: An Analysis of the National Inpatient Sample

Sachin Prasad, Danielle Thor, Tony Elias, Monisha Singh
Journal of the Endocrine Society
Diagnosis and Treatment of Venous Diseases
article

SAT-135 Clinical Outcomes for Patients with PCOS and COVID 19: An Analysis of the National Inpatient Sample

Sachin Prasad, Danielle Thor, Tony Elias, Monisha Singh
article en

Abstract

Abstract Disclosure: D.C. Thor: None. T. Elias: None. M. Singh: None. S. Prasad: None. Clinical Outcomes for Patients with PCOS and COVID-19: An Analysis of the National Inpatient SampleIntroduction: As clinicians continue to improve their recognition and management of polycystic ovarian syndrome (PCOS), it remains imperative to understand the health outcomes for these patients over time. Limited data is available on the comorbid correlations for the PCOS population.Objectives: We sought to examine the National Inpatient Sample (NIS) database to describe in-hospital outcomes among patients with PCOS and an active COVID-19 infection.Methods: Data were extracted from the NIS database from 2019 and 2020. The NIS was searched for hospitalizations of all patients greater than 18 years old who had PCOS. We then analyzed the outcomes of patients with COVID-19. Multivariate logistic regression analysis was used to adjust for confounders. The primary outcome was inpatient mortality and secondary outcomes were annotated accordingly. SPSS software was used for statistical analysis, and all results were powered to p<0.001.Results: This study included 32,385 patients with PCOS, of which 586 (1.81%) were identified as having an active COVID-19 infection. Multivariate regression demonstrated that COVID-19 patients with PCOS had higher inpatient mortality (OR 1.160, CI 1.066-1.262, p<0.001). On secondary analysis, PCOS patients with COVID-19 were more likely to have systemic lupus erythematosus (OR 1.025, CI 1.005-1.046), anemia (OR 1.016, CI 1.013-1.019), thrombocytopenia (OR 1.037, CI 1.024-1.050), hypertension (OR 1.022, CI 1.013-1.030), chronic kidney disease (OR 1.020, CI 1.010-1.030), acute renal failure (OR 1.038, CI 1.027-1.049), chronic obstructive pulmonary disease (OR 1.020, CI 1.009-1.032), pulmonary hypertension (OR 1.021, CI 1.003-1.040), severe liver disease (OR 1.013, CI 1.003-1.024), all-cause arrhythmias (OR 1.019, CI 1.009-1.028), all-cause shock (OR 1.060, CI 1.015-1.107), all-cause heart block (OR 1.026, CI 1.001-1.052), all-cause sepsis (OR 1.049, CI 1.041-1.058), all-cause coagulopathy (OR 1.031, CI 1.020-1.042), all-cause heart failure (OR 1.022, CI 1.012-1.032), all-cause stroke (OR 1.023, CI 1.012-1.034), and all-cause myocardial infarction (OR 1.023, CI 1.008-1.039).Conclusion: In this nationally-representative, population-based retrospective cohort study, hospitalized patients with PCOS and COVID-19 were associated with higher mortality and worse outcomes. Further analysis and/or discussion is necessary to improve the care of this potentially underserved population. Presentation: Saturday, July 12, 2025

Journal of the Endocrine SocietyVol. 9(Supplement_1)
Stratford University (US), Rowan University (US)
Openalex Percentile: Top 52%
Diagnosis and Treatment of Venous Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.